Nanoparticles for the treatment of ocular neovascularizations

European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V
Robert Hennig, Achim Goepferich

Abstract

Neovascular diseases of the posterior eye like age-related macular degeneration, proliferative diabetic retinopathy or retinopathy of prematurity carry a tremendous burden for patient and health care system alike. Although intravitreal injections of anti-VEGF based therapeutics have significantly improved the visual outcome for many patients, current therapeutic options still show significant drawbacks such as the injection-related risk of contracting an infection. Due to their ability to encapsulate drugs with otherwise poor bioavailability, accumulate in areas of increased vascular permeability and control the release of active ingredients over time, nanoparticle systems have been widely researched to enhance current therapeutic strategies and expand the therapeutic arsenal. In this review, emphasis is placed both on the possibilities and drawbacks that a systemic nanoparticle-based therapy could have in the context of neovascular posterior eye diseases. Recent investigations into intravenous and intravitreal administration of nanomaterials and their potential to deliver potent drugs and genes to pathologic lesions will also be presented. Furthermore, we will focus on the exceptional anti-oxidative and anti-angiogenic propert...Continue Reading

References

Dec 1, 1975·The Journal of Cell Biology·H G RennkeM A Venkatachalam
Feb 1, 1991·Experimental Eye Research·M E LanghamM Sebag
Mar 1, 1987·Survey of Ophthalmology·R W Young
Apr 1, 1986·Archives of Dermatology·S E Koch
Jul 1, 1980·The British Journal of Ophthalmology·S MelamedY Ben-Shaul
Jan 1, 1980·Cancer Chemotherapy and Pharmacology·K Lu, T L Loo
May 1, 1995·Kidney International·W D Comper, E F Glasgow
Apr 1, 1995·Ophthalmology·E FriedmanE S Gragoudas
Sep 3, 1996·Proceedings of the National Academy of Sciences of the United States of America·M FriedlanderD A Cheresh
Oct 9, 1996·JAMA : the Journal of the American Medical Association·J M SeddonS E Hankinson
Apr 29, 1998·The Journal of Clinical Investigation·G ThurstonD M McDonald
Nov 12, 1998·The American Journal of Pathology·T TobeP A Campochiaro
Aug 15, 2002·Proceedings of the National Academy of Sciences of the United States of America·Jocelyn HolashJohn S Rudge
Feb 25, 2003·Progress in Retinal and Eye Research·A N WitmerR O Schlingemann
Feb 26, 2003·Investigative Ophthalmology & Visual Science·Uday B KompellaSurya P Ayalasomayajula
Mar 12, 2003·Advanced Drug Delivery Reviews·Jayanth Panyam, Vinod Labhasetwar
May 15, 2003·Survey of Ophthalmology·Jayakrishna AmbatiAnthony P Adamis
Jun 5, 2003·Nature Medicine·Christopher W Pugh, Peter J Ratcliffe
Jul 29, 2003·Investigative Ophthalmology & Visual Science·Jean-Louis BourgesFrancine F Behar-Cohen
Aug 2, 2003·Nature Reviews. Neuroscience·Joyce Tombran-Tink, Colin J Barnstable
Sep 26, 2003·Investigative Ophthalmology & Visual Science·Ursula Schmidt-ErfurthGottfried O H Naumann
Feb 27, 2004·Biochimica Et Biophysica Acta·Curzio RüeggAgnese Mariotti
Sep 8, 2004·Trends in Molecular Medicine·Tongalp H TezelHenry J Kaplan
Oct 29, 2004·Nature Reviews. Cancer·Carl-Henrik HeldinArne Ostman
Dec 31, 2004·The New England Journal of Medicine·Evangelos S GragoudasUNKNOWN VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group
Mar 5, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sophia RanPhilip E Thorpe
Apr 27, 2005·Investigative Ophthalmology & Visual Science·Nirbhai SinghBalamurali K Ambati

❮ Previous
Next ❯

Citations

Oct 24, 2015·Journal of Controlled Release : Official Journal of the Controlled Release Society·Robert HennigAchim Goepferich
Mar 2, 2017·Pharmaceutical Patent Analyst·Paulina A Kulyavtsev, Roxanne P Spencer
Jul 25, 2017·ACS Applied Materials & Interfaces·Raghu GanugulaMajeti N V Ravi Kumar
Dec 28, 2019·Pharmaceutics·Natallia DubashynskayaYury A Skorik
Jan 8, 2020·Pharmaceutics·Olga OsipovaEvgenia Korzhikova-Vlakh
Aug 31, 2016·Expert Opinion on Drug Delivery·Mary JosephAshim K Mitra
Dec 16, 2018·International Journal of Molecular Sciences·Erika GucciardoKaisa Lehti
Feb 20, 2019·Nature Communications·Yanfei WangDaniel S Kohane
Nov 2, 2020·Journal of Controlled Release : Official Journal of the Controlled Release Society·Aira Sarkar, Sathish Dyawanapelly
Nov 18, 2020·Experimental Eye Research·Shibani SupeKavita Singh
Jan 20, 2020·Ophthalmic Research·Xiaoyan Pan, Yang Lv

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft
Klinische Monatsblätter für Augenheilkunde
Aktuelle Stellungnahme der Retinologischen GesellschaftBerufsverbands der Augenärzte Deutschlands e. V
Progress in Brain Research
R O Schlingemann, A N Witmer
International Ophthalmology Clinics
Richard C Lin, Philip J Rosenfeld
© 2022 Meta ULC. All rights reserved